In this episode, we speak with Jim Foote, CEO of First Ascent Biomedical, about functional precision medicine and why testing drugs on a patient’s own tumor cells could transform cancer treatment. Jim explains how their CLIA-certified lab cultures live cancer cells and uses robotics and AI to test hundreds of drug combinations in just 10 days, achieving an 83% correlation with patient outcomes in a Nature Medicine study. We discuss why this approach differs fundamentally from genomic sequencing, hear powerful patient stories, and explore how converging technologies in robotics, AI, and cloud computing have finally made individualized cancer treatment possible at scale.